In colon and gastric cancer, the upregulation of PAK6 promotes cancer progression and chemotherapy resistance, while in clear cell renal cell carcinoma and hepatocellular carcinoma, its downregulation is linked to cancer progression and patients’ survival [174,175,176,177]. This evidence concerns the gene PAK6 and cancer.